NCT05470114View on ClinicalTrials.gov

A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 19, 2022

Primary Completion Date

June 7, 2023

Study Completion Date

October 9, 2023

Conditions
Atopic Dermatitis
Interventions
DRUG

LEO 138559

LEO 138559 is an antibody given by subcutaneous injection.

DRUG

Dupixent®

Dupixent® is an antibody given by subcutaneous injection.

Trial Locations (1)

1090

LEO Investigational Site, Vienna

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY